InspireMD Beats Q2 Estimates on International Growth Despite U.S. Product Recall

Key Facts

In a move reflecting corporate resilience amid regulatory hurdles, InspireMD reported second-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a loss per share of -$0.17, performing better than the anticipated -$0.20 loss, while quarterly revenue reached $1.77 million against estimates of $1.38 million. This performance was primarily driven by a 21% international growth in the CGuard platform, which helped mitigate the impact of a voluntary U.S. recall of the CGuard Prime system in May.

These results come as the company restructures its leadership in preparation for a U.S. market re-launch, highlighted by the appointment of Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. According to reports, robust international expansion has effectively offset the financial pressures stemming from the recall of its carotid stent delivery system. The company is currently focused on implementing design modifications to address the technical issues identified during the recall process.

Looking ahead, market participants are monitoring the success of the U.S. re-launch strategy and the impact of new leadership on market share. While current price levels for NSPR are unavailable at this time, focus remains on the sustainability of international sales growth. Investors are also watching broader U.S. economic catalysts, including the Consumer Price Index (CPI) release on August 12, 2026, which may influence overall healthcare sector sentiment.